2-Methyl-1-(3-methylcyclopentyl)propan-1-one | 31577-82-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Methyl-1-(3-methylcyclopentyl)propan-1-one
• CAS: 31577-82-9
• 化学式: C₁₀H₁₈O
• 分子量: 154.252
• InChiKey: GEUINYLILIYHOG-UHFFFAOYSA-N

物化性质

• 沸点：
  200.1±8.0 °C(Predicted)
• 密度：
  0.889±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  (E)-5-(3,3-dimethyloxiran-2-yl)-3-methylpent-2-enyl acetate 在 镍 硫酸 、 氢气 、 对甲苯磺酸 作用下， 以 甲苯 为溶剂， 25.0 ℃ 、15.0 MPa 条件下， 生成 2-Methyl-1-(3-methylcyclopentyl)propan-1-one
  参考文献：
  名称：

  Lizzani,L.; Luft,R., Bulletin de la Societe Chimique de France, 1971, p. 198 - 200

  摘要：

  DOI：

文献信息

• Heterobicyclic metalloprotease inhibitors
  申请人：Steeneck Christoph

  公开号：US20090137547A1

  公开（公告）日：2009-05-28

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
• HETEROBICYCLIC METALLOPROTEASE INHIBITORS
  申请人：Steeneck Christoph

  公开号：US20120015920A1

  公开（公告）日：2012-01-19

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
• BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：US20180057505A1

  公开（公告）日：2018-03-01

  The compounds of formula I, wherein the variables are as defined herein, and pharmaceutically acceptable salts thereof are useful as inhibitors of the PAR-2 signaling pathway. The compounds of formula I and pharmaceutically acceptable compositions comprising such compounds can be employed for treating various diseases, disorders, and conditions.
• US7795245B2
  申请人：——

  公开号：US7795245B2

  公开（公告）日：2010-09-14
• Lizzani,L.; Luft,R., Bulletin de la Societe Chimique de France, 1971, p. 198 - 200
  作者：Lizzani,L.、Luft,R.

  DOI：——

  日期：——